Jaffer A. Ajani, MD, spoke about the recent approvals of nivolumab plus ipilimumab and nivolumab plus chemotherapy for patients with esophageal squamous cell carcinoma.
Approval Alert | Nivolumab-Based Regimens for Esophageal Squamous Cell Carcinoma
The FDA has granted approval to nivolumab plus ipilimumab and nivolumab plus chemotherapy for patients with unresectable advanced or metastatic esophageal squamous cell carcinoma.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer
2
Zenocutuzumab Earns FDA National Priority Voucher in Cholangiocarcinoma
3
FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy
4
124 Real-World Progression-Free Survival 2 and Tumor Response of CDK4/6is + Aromatase Inhibitor in Patients With HR+/HER2– Metastatic Breast Cancer
5